Sign in
4

Changes in Ownership

Adaptimmune Therapeutics PLC Filed Acc 0001104659-19-048518

Options or other derivatives

  • CEO and CFO acquired 769,320 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Rawcliffe Adrian CEO and CFO 2019-09-01 Grant or award · Option to purchase Ordinary Shares +628,872 628,872 D
Rawcliffe Adrian CEO and CFO 2019-09-01 Grant or award · Option to purchase Ordinary Shares +140,448 140,448 D
Loading xslF345X03/a4.xml…